| Project/Area Number |
21591001
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Saitama Medical University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2011: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2010: ¥2,600,000 (Direct Cost: ¥2,000,000、Indirect Cost: ¥600,000)
Fiscal Year 2009: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
|
|---|
| Keywords | EZH2 / 非小細胞肺癌 / 予後予測因子 / ゲノムワイド / 個別化医療 / H3K27 / ChIP-on-chip / Effector / CHIP-on-chip / 転移 / 浸潤 / siRNA / 予後診断マーカー |
|---|
| Research Abstract |
Using immunohistochemistry for EZH2, we showed that the EZH2-expressing group reduced survival of stage I NSCLC compared with the non-EZH2-expressing group. In COX proportional hazard models, the non-EZH2-expressing group was independently associated with prolonged survival. These results suggest that EZH2 can be a novel predictive factor for prognosis in postsurgical NSCLC at stage I. Furthermore, using shRNA-mediated knockdown of EZH2 expression, in vitro cell growth assay and matrigel invasion assay showed that the suppression of EZH2 expression inhibited cellular proliferation and reduced invasion and metastatic potentials. Thus, EZH2 may function as an oncogene.
|
